Insider buying
~$50K81K sh @ $0.62
Traded Aug 26, 2025 · filed 2 days later
The CEO of Relmada Therapeutics paid $50K out of pocket for Relmada Therapeutics shares. Shares held went up 11% with this purchase.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Aug 28, 2025 · Filed Aug 28, 2025
The CEO of Relmada Therapeutics paid $41K out of pocket for Relmada Therapeutics shares. Shares held went up 6% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$41,422
Shares × reported transaction price
$25K–$100K
+5.9%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 0 months
Confirmed open-market purchases by the same insider in the available history
No
Compared with 5 earlier confirmed purchases
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals about 2.3% of the CEO's reported total pay for fiscal 2024 ($1.8M)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-17. The proxy names Sergio Traversa as CEO for that year. A size comparison, not a judgement
21 days after results of Aug 7, 2025, 77 days before results of Nov 13, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +47.3% | +0.3% | +47.0% |
| 30 days | +67.9% | +2.9% | +65.0% |
| 90 days | +302.7% | +5.9% | +296.7% |
| 180 days | +306.3% | +7.5% | +298.8% |
| 365 days | +289.3% | +18.9% | +270.4% |
Past results only. Not a forecast.
Insider buying
Traded Aug 26, 2025 · filed 2 days later
The CEO of Relmada Therapeutics paid $50K out of pocket for Relmada Therapeutics shares. Shares held went up 11% with this purchase.
Insider buying
Traded Aug 27, 2025 · filed 1 day later
The CEO of Relmada Therapeutics paid $87K out of pocket for Relmada Therapeutics shares. Shares held went up 16% with this purchase.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.